Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
Antibody discovery for complex fibrosis targets requires advanced platforms capable of addressing difficult biology. Alloy Therapeutics partnered with Mediar to accelerate high-quality antibody programs into IND-enabling studies.
Accelerated Antibody Discovery for Complex Fibrosis Targets
Accelerating Antibody Discovery for Challenging Fibrosis Targets Download Case Study Contact Us Advancing a first-in-class fibrosis program against complex biology This case study highlights how Alloy’s antibody discovery platforms and execution model enabled Mediar Therapeutics to move a complex fibrosis program forward with speed and confidence, despite biological and technical barriers that stalled conventional discovery […]
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
Collaboration combines Alloy’s antibody discovery and engineering platforms with Torpedo’s radiopharmaceutical development capabilities – including Terbium-161 – to advance next-generation oncology RLT candidates toward clinical development
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]
De-risking antibody discovery through comprehensive developability profiling
De-risking antibody discovery through comprehensive developability profiling Download Tech Note Contact Us Select leads with confidence by integrating biophysical assays, computational analysis, and clinical benchmarking from the earliest stages of discovery. Despite strong target binding, many therapeutic antibodies fail late in development due to preventable issues related to stability, manufacturability, or pharmacokinetics. Alloy’s integrated developability […]
Poster | A Fully Integrated GPCR Antibody Discovery Workflow
Overcoming challenges in GPCRs with a fully integrated high-throughput antibody discovery workflow Download the poster Contact Us Poster Overview: Transform your approach to GPCR antibody discovery with this detailed poster that demonstrates how Alloy Therapeutics’ PerformAbTM yeast display platform and innovative technologies can overcome significant challenges in targeting these complex transmembrane proteins. Download the poster […]
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]
Highly Specific anti-WT1/HLA-A2 TCRm Antibodies
New Data: unlocking the potential of TCRm antibodies Download the poster and explore the discovery of highly specific anti-WT1/HLA-A2 TCR-like antibodies. Download the poster Contact Us Keyway™ TCRm antibody discovery platform is revolutionizing immunotherapy development In a significant study, Alloy Therapeutics researchers identified T Cell Receptor mimic (TCRm) antibodies with exceptional specificity for the Wilms […]
Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
